Superselective cisplatin (CDDP)-carboplatin (CBDCA) combined infusion for head and neck cancers.
A group of 26 patients with carcinoma of the head and neck region was treated by superselective intra-arterial infusion of cisplatin (CDDP)-carboplatin (CBDCA). The tumor locations included the tongue (n = 4), oral base (n = 2), nasopharynx (n = 2), oropharynx (n = 8), hypopharynx (n = 4) and larynx (n = 4). Using the coaxial technique, a microcatheter was placed in the lingual, ascending pharyngeal, facial and superior thyroidal arteries according to the location of the tumor. Under imaging studies, CDDP (50 mg/m2)-CBDCA (300 mg/m2) was infused into the vessel, via injectors at the rate of 12.5 ml/min. One to five injections were given every 4 weeks. During and following the chemotherapy the patients received radiotherapy (n = 22), surgery (n = 4) or both (n = 3). Sixty-six sessions of intra-arterial chemotherapy were given with no major complications. Drug-related systemic side effects were mild. The overall response rate was 96% (complete response (CR) 50% and partial response (PR) 46%). Superselective CDDP-CBDCA combined infusion is feasible, relatively non-toxic, and important as multimodality therapy.
Imai
S
S
Department of Diagnostic Radiology, Kawasaki Medical School, Okayama, Japan.
Kajihara
Y
Y
Munemori
O
O
Kamei
T
T
Mori
T
T
Handa
T
T
Akisada
K
K
Orita
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D002406:Catheterization, Peripheral / Q000295:instrumentation; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy / Q000601:surgery; D007261:Infusions, Intra-Arterial; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000601:surgery; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000601:surgery; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000601:surgery; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D014062:Tongue Neoplasms / Q000188:drug therapy / Q000601:surgery
D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin